Prostate cancer incidence varies more than 25-fold worldwide, largely due to the widespread practice of prostate specific antigen (PSA) testing and subsequent biopsy [1]. It is the second most frequently diagnosed cancer of men (914.000 new cases per year, accounting for 13.8% of total cancer cases) and the 5th most common cancer overall worldwide. The incidence is expected to grow to 1.7 million new cases and 499.000 deaths by 2030, mainly due to the growth and aging of the global population [2]. [...]